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INTRODUCTION 
 
 Myasthenia gravis is a neuro-muscular junction disorder characterized 
by skeletal muscle weakness and fatiguability. It is due to a decrease in the 
number of available acetylcholine receptors at the neuromuscular junction 
as a result of antibody mediated autoimmune attack.  
 
 Weakness of muscles may involve cranial and somatic musculatures. 
Weakness resembling myasthenia gravis may occur in other conditions as a 
result of drug, endocrine disease of thyroid, certain malignancies, bacterial 
toxins and also by non-autoimmune mechanisms involving the 
neuromuscular junction.  
 
 The weakness may involve all the skeletal muscles of the body but 
the distribution of weakness has a characteristic pattern and there is a 
diurnal variation of symptoms. If the weakness of respiratory muscles 
becomes so severe as to require respiratory assistance, then it is called 
myasthenic crisis. 
 
 The myasthenia may be generalized one involving all the groups of 
muscles or it may involve the extra ocular muscles and facial muscles. 
Sometimes the bulbar muscles alone may be involved and the condition is 
called bulbar myasthenia gravis.  
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 In some of the patients, (anti-AchR) Acetyl choline receptor 
antibodies may be positive and in some it will be negative. In some of the 
patients, anti-muscle specific tyrosine kinase antibodies will be positive and 
negative in some of the patients. 
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AIM OF THE STUDY 
 
 To study the predisposing factors, clinical features, associated 
complications and treatment outcome in patients with myasthenic 
crisis. 
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REVIEW OF LITERATURE 
 
MYASTHENIA GRAVIS AND CRISIS 
Epidemiology: 
 Myasthenia gravis can occur in any age group from infancy to old 
age. There is a considerable variation in the incidence and prevalence of 
myasthenia around the world 
(12)
. Biological and genetic factors play a role 
for this variability. In the United States, the prevalence rate is 20 per 100000 
population with a total of 60000 cases 
(1)
. 
 
Gender and age influence the incidence of Myasthenia gravis. The 
disease is three times more common in women than men before the age of 
40 years. The incidence is higher in males after 50 years of age. The 
incidence is equal during puberty. 
 
Pathophysiology 
 Acetyl choline is synthesized in the motor nerve terminal at the 
neuromuscular junction and is stored in vesicles. When an action potential 
reaches the nerve terminal, Ach is released from 150-200 vesicles and this 
11 
 
combines with Acetyl choline receptors which are densely packed at the 
peaks of post synaptic folds. The structure of acetyl choline receptor 
consists of five sub units – 2α, 1β, 1  and 1  or  arranged around a central 
pore. When acetyl choline combines with the binding sites on the α subunits 
of AchR, the channel in the AchR opens, resulting in rapid entry of cations, 
especially sodium, causing depolarization of the end plate region of muscle 
fibre. If the depolarization is large enough, it causes an action potential that 
spreads along the muscle fibre, initiating muscle contraction. This process is 
rapidly terminated by hydrolysis of Ach by acetylcholinesterases which is 
present in the synaptic folds and diffusion of Ach away from the receptor. 
 
In Myasthenic gravis, the defect is a decrease in the number of 
available AchRs at the post synaptic muscle membrane and the post 
synaptic folds are flattened resulting in decreased efficiency of 
neuromuscular transmission. Even though Ach is released normally, it 
produces small end plate potentials that fails to trigger muscle action 
potentials. Failure of transmission at multiple neuromuscular junctions 
causes weakness of muscle contraction. 
 
The amount of Ach released for each impulse normally declines on 
repeated activity (called presynaptic rundown). In myasthenic patients, the 
decreased efficiency of neuromuscular transmission combined with normal 
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rundown results in the activation of fewer and fewer muscle fibres by 
successive nerve impulses and hence increasing muscle weakness. This 
accounts for decremental response to repetitive nerve stimulation on 
electrodiagnostic testing. 
 
In myasthenia gravis, the neuromuscular abnormalities are brought 
about by an autoimmune response mediated by specific anti-AchR 
antibidoes. The anti-AchR antibodies reduce the number of available AchRs 
at the neuromuscular junctions by three mechanisms. 
i) Accelerated turnover of AchRs by cross-linking and rapid 
endocytosis of receptors. 
ii) Blockade of active site of AchR 
iii) Damage to the post synaptic muscle membrane by antibody 
and complement. 
An immune response to muscle-specific kinase (MUSK) can also 
result in myasthenia gravis by interfering with AchR clustering. The 
pathogenic antibodies are IgG and are T-cell dependent. 
 
Immunopathology: 
 The AchR antibodies bind to AchR on the terminal expansions of the 
junctional folds and cause complements mediated destruction of folds and 
increased degradation of AchR. These antibodies block Ach from binding to 
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AchR 
(29)
. Destruction of the junctional folds leads to simplication and 
distortion of the post-synaptic region and functional loss of AchR. This 
causes neuromuscular transmission failure and muscle weakness 
(29)
. CD4 T 
cells are present in increased numbers in these patients which regulate the 
AchR antibody production. The α-subunit  of AchR bears T-cell recognition 
sites. Sensitization to CD4 T-cells occurs on the AchR complex and the T-
cells recognize multiple epitopes on the AchR α-subunit (14). Low affinity 
IgG antibodies are reported in two-thirds of myasthenic patients who are 
seronegative
(30)
. Many subtypes of myasthenia gravis are identified basing 
on clinical presentation, age of onset, thymic pathology and autoantibody 
profile
(12)
. 
 
Generalised MG:  
 Generalised myasthenic gravis may be either early onset or late onset 
type. Early onset myasthenia gravis occurs in females before 40 years of 
age, have anti Ach-R antibodies and enlarged hyperplastic thymus gland. 
Late onset disease occurs in males, have antibodies to striated muscle 
proteins like titin, and ryanodine receptors in addition to Ach-R antibodies. 
The presence of anti-muscle antibodies, especially anti-ryanodine receptor 
antibodies is associated with more severe generalized or oropharyngeal 
weakness and myasthenic crisis 
(33)
. 
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Thymomatous MG: 
 Thymoma is present in 10% to 15% of myasthenia gravis. Thymoma 
associated myasthenia has equal frequency in males and females and may 
occur at any age with peak age of onset at 50. 
 
In myasthenia gravis, the thymas is abnormal in 75% of patients. In 
65% the thymus is hyperplastic with active germinal centres and the 
hyperplastic thymus is not necessarily enlarged. 10% of patients have 
thymomas. Muscle like cells within the thymus which bear AchRs on their 
surface serve as a source of autoantigen and trigger the autoimmune reaction 
within the thymus gland. Neoplastic epithelial cells in thymomas express 
numerous self-like antigens, including AchR, titin and ryanodine receptor-
like epitopes. The regulation of auto reactive T-cells may be impaired in 
thymoma due to a deficiency in the expression of the autoimmune regulator 
gene and selective loss of T-regulatory cells in human thymoma.
(12)
 
 
Clinical Features: 
 The clinical manifestation of myasthenia gravis is weakness and 
fatiguability of muscles. The weakness increases during repeated use and 
improves after rest or sleep. The course is variable. Exacerbations and 
remissions may occur during the first few years after the onset of the 
disease. Remissions are rarely complete or permanent. Any systemic 
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disorders or unrelated infections often precipitates increasing myasthenic 
weakness and causes crisis. 
 
 The weakness of muscle has a characteristic pattern of distribution. 
The lids and extra ocular muscles are often affected early in the course of 
myasthenic gravis and diplopia and ptosis are the initial symptoms. Later 
facial and oro-pharyngeal muscles are affected. Facial weakness produces a 
snarling expression when attempting to smile. Weakness in chewing is 
noticeable after prolonged effort. Difficulty in swallowing may occur due to 
weakness of palate, tongue or pharynx resulting in nasal regurgitation, 
aspiration of liquids or food. Speech will be of nasal timbre due to weakness 
of palate or a dysarthric mushy quality due to tongue weakness. Bulbar 
weakness is common in Musk antibody positive Myasthenia gravis. In 85% 
of patients, the weakness is generalized, affecting the limb muscles as well. 
If weakness is restricted to the extracular muscles for 3 years, it is unlikely 
that it will become generalized, and they are classified to have ocular 
myasthenia gravis. Asian patients have predominant ocular myasthenia 
gravis in upto 58% of all myasthenic patients. The limb weakness in 
myasthenia gravis is often proximal and asymmetric. Inspite of weakness, 
deep tendon reflexes are preserved. If the respiratory muscles become weak, 
it requires respiratory assistance and the patient is said to be in crisis.  
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Association of Myasthenic Gravis with other diseases: 
Myasthenic gravis is associated with other immune mediated diseases 
like hyperthyroidism, rheumatoid arthiritis, seizure in children, diabetes 
mellitus and extra thymic neoplasm. Extra thymic malignancies are reported 
in older age patients and is possibly due to immune dysregulation. 
(38)
 
 
Diagnosis: 
 The diagnosed is based on the typical distribution of weakness and 
fatiguability without loss of reflexes or impairment of sensation or other 
neurologic function. The diagnosis is confirmed by investigatiosn because; 
1. Other treatable conditions may resemble myasthenia gravis and 
2. The treatment of myasthenia gravis may involve surgery and the 
prolonged use of drugs with its adverse side effects. 
 
Antibodies to AchR or Musk: 
 Anti-AchR antibodies are detectable in the serum of 85% of all 
myasthenic patients but in 50% of patients with ocular myasthenia gravis. 
The presence of Anti-AchR antibodies is diagnostic of myasthenia gravis 
and negative test does not rule out the disease.  The measured level of 
antibodies do not correspond with the severity of disease but a treatment 
induced fall in antibody level correlates with clinical improvement. Anti-
musk antibodies are present in 40% AchR antibody negative generalized 
myasthenia gravis patients. Musk antibodies are rarely present in AchR 
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antibody positive patients or in patients with MG limited to ocular muscles. 
There in evidence that Myasthenia gravis patients without antibodies to 
AchR or Musk have undefined antibodies that impair neuromuscular 
transmission. Antistriational muscle antibodies occur in increasing 
frequency in older patients and in patients with more severe disease. This 
suggests that  disease severity is related to humoral response against 
multiple muscle antigens. 
(33)
 
 
Electrodiagnostic Testing: 
Repetitive nerve stimulation: 
Anti-AchE medication is withheld 6-24 hours before testing. Weak 
muscles are tested by delivering electric shocks of 2-3 Hz per second to 
appropriate nerves and action potentials are recorded from the muscles. In 
myasthenic patients, there is a rapid reduction of >10-15% in the amptitude 
of the evoked responses. A single dose of edrophomium is given to prevent 
or diminish this decremental response as a further test. The sensitivity of 
RNS is diagnosing Myasthenia Gravis is from 53% to 100% in generalized 
myasthenia gravis and in ocular myasthenia gravis it is 10% to 48% 
(35)
.
 
The 
most sensitive test of neuro muscular transmission is the single fibre EMG. 
There is increased jitter in some muscles in all patients with Myasthenia 
Gravis 
(35)
. The jitter can be measured with concentric needle electrode as an 
alternative to specially designed single fibre electrode 
(36)
.
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Edrophonium Test:  
 Drugs that inhibit the enzyme AchE allow Ach to interact repeatedly 
with the limited number of AchRs, producing improvement in the strength 
of myasthenic muscles. Edrophonium is used for diagnosis because of its 
rapid onset of action (30 sec) and short duration (5 min) of its effects. The 
weakness of extra ocular muscles, impairment of speech or the length of 
time that the patient can maintain the arms in forward abduction are 
evaluated. Initially, 2mg of edrophonium i.v. is given. If there is definite 
improvement, the test is positive and is stopped. If there is no change, an 
additional 8mg iv is given either in two parts or single dose because some 
patients develop side effects like nausea, diarrhoea, salivation, fasciculation 
and rarely of syncope or bradycardia. These side effects are reported in 
0.16% edrophonium tests. If there is troublesome side effects, atropine iv be 
given.  
 
 False positive tests occur in other neurologic disorders like 
amyotrophic lateral sclerosis, in placebo reactors, Eaton-Lambert syndrome, 
intracranial aneurysm, brainstem lesions, congenital myasthenic syndrome, 
cavernous sinus tumors, end stage renal disease and muscle disease 
affecting the ocular muscles. False-negative (or) equivocal tests may also 
occur. The edrophonium test is reserved for patients with clinical findings 
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suggestive of myasthenia gravis but who have negative antibody and nerve 
conduction studies. The edrophonium test is positive in 60% to 95% of 
patients with ocular myasthenia gravis and in 72% to 95% of generalized 
myasthenic gravis 
(15)
. The optimal edrophonium dose can not be 
predetermined. The average dose of edrophonium to give a positive 
response was 3.3mg for ptosis and 2.6mg for dysfunction of ocular muscles 
(16)
. 
 
Congenital myasthenic syndromes: 
 These are a heterogenous group of disorders of neuromuscular 
junction that are not autoimmune but are due to genetic mutations in which 
any component of the neuromuscular junction may be affected. Alteration in 
function of presynaptic nerve terminal or in the various subunits of the 
AchR or AchE have been identified. The congenital myasthenic syndromes 
share many of the clinical features of autoimmune myasthenia gravis. 
Congenital myasthenic syndromes should be suspected when symptoms of 
myasthenia have begun in infancy or childhood and AchR antibody tests are 
consistently negative. 
 
Differential Diagnosis: 
Conditions that cause weakness of the cranial or somatic musculature are; 
i) Non-autoimmune Congenital Myasthenic Syndromes 
ii) Drug induced Myasthenia 
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iii) Eaton-Lambert myasthenic syndrome 
iv) Neuroasthenia 
v) Hyperthyrodism 
vi) Botulism 
vii) Intracranial mass lesions and 
viii) Progressive external ophthalmoplegia 
 
 Oropharyngeal muscle weakness causes changes in the voice, 
difficulty in chewing and swallowing and inadequate maintenance of the 
upper airway. A history of frequent choking or throat clearing or coughing 
after eating indicates difficulty in swallowing. Respiratory dysfunction and 
isolated dysphagia (without dysarthria) are rarely the initial symptoms of 
myasthenia gravis. There will be jaw weakness. 
 
 Weakness begins in limb or axial muscles in about 20% of MG 
patients
(2)
. Any trunk or limb muscle may be weak, but some are more often 
affected than others. Neck flexors are usually weaker than neck extensors 
and the deltoid, triceps and the extensors of the wrist and fingers and ankle 
dorsiflexors are frequently weaker than other limb muscles.  Rarely, MG 
presents initially with focal weakness in single muscle groups, such as 
“dropped head syndrome” due to severe neck extensor weakness or isolated 
vocal cord or respiratory muscle weakness. In untreated patients with long 
standing disease, weakness may be fixed and severely involved muscles 
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may be atrophic, giving the appearance of a chronic myopathy. This is 
likely in muscle-specific tyrosine kinase antibody – positive myasthenia 
gravis. 
 
MUSK – Antibody Myasthenia Gravis 
 Antibodies to Musk have been reported in upto 50% of patients with 
generalized myasthenia gravis who lack Ach antibodies
(5)
 and have been 
recently reported in ocular myasthenia gravis as well 
(3,4)
. The incidence of 
Musk-antibody myasthenia gravis is highest closer to equator and lowest 
closer to the poles 
(6)
. Genetic and environmental factors play a role. MMG 
affects females and begins from childhood through middle age. In same, the 
clinical findings are indistinguishable from Anti-AchR positive MG. Many 
MMG patients have predominant weakness in cranial and bulbar muscles, 
frequently with marked atrophy of these muscles. Others have prominent 
neck, shoulder and respiratory weakness with little or no involvement of 
ocular or bulbar muscles. The electro diagnostic abnormalities may not be 
widespread as in other forms of MG, and it may be necessary to examine 
different muscles to demonstrate abnormal neuromuscular transmission 
(37)
. 
 
 Many MMG patients do not improve with cholinesterase inhibitors, 
some become worse and many have profuse fasciculations with these 
drugs
(13)
. 
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 Disease severity tends to be worse but most improve dramatically 
with plasma exchange or corticosteroids 
(11)
. More immuno suppression is 
typically necessary, though long term outcome is generally good 
(5)
. Thymic 
changes are absent or minimal 
(9,10)
. The role of thymectomy in MMG is not 
yet clear 
(5, 11)
. 
 
Seronegative Myasthenia Gravis: 
 Some MG patients lack both anti-AchR and anti-MUSK antibodies 
(“double seronegative MG”). They are clinically heterogenous. The true 
frequency of seronegative MG may be quite low. 
 
Genetics of Myasthenia Gravis: 
 The family members of patients are 1000 times more likely to 
develop the disease than the general population. 33% to 45% of 
asymptomatic first degree family members show jitter on SFEMG testing 
and anti-AchR antibodies are slightly elevated in upto 50%. Certain HLA 
types (DR2, DR3, B8, DR1) predispose to MG. MMG is associated with 
HLA-DR14 & DQ5. In asian patients, an association of OMG with HLA-
BW46 in Chinese patients have been reported 
(8)
. Non-HLA genes are also 
reported to be associated with MG. 
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“Ice-Pack” Test 
 Ice Pack is applied over the drooped eyelid for 2 minutes and 
improvement in ptosis is assessed. Positive responses occur even when 
tensilon test is negative or it is contraindicated and it has a high sensitivity 
and specificity 
(7)
. 
 
Treatment 
 There is a good prognosis in myasthenic patients and they can return 
to normal life after proper therapy.  
 
The most useful treatments are  
1) Anticholinesterase drugs 
2) Immuno suppressive agents 
3) Thymectomy 
4) Plasmapheresis 
5) Intravenous immunoglobulin 
 
Anticholinestrase Drugs: 
 There is a partial improvement in most myasthenic patients and 
improvement is complete in only a few. Although, neostigmine and 
Pyridostigmine are the drugs useful in these patients, Pyridostigmine is most 
widely used drug. The beneficial action of pyridostigmine begins within 15-
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30 minutes and lasts for 3-4 hours and treatment is begin with a moderate 
dose of 30-60mg three or four times daily. The maximum useful dose of 
pyridostigmine rarely exceeds 120mg every 3-6 hrs during day time. Over 
dosage with anticholinesterase drug may cause increased weakness and 
other side effects. In some patients, muscaric side effects like nausea, 
salivation, abdominal cramps and diarrhea may limit the dose tolerated. 
Atropine / diphenoxylate or loperamide are useful for these symptoms. 
 
Thymectomy: 
 Thymectomy is done for surgical removal of thymoma and as a 
treatment of myasthenia gravis. In the absence of tumour, the evidence 
suggests that upto 85% of patients experience improvement after 
thymectomy; 35% of these achieve drug free remission 
(21)
. The 
improvement is delayed for months to years. As a long term benefit, 
thymectomy diminishes or eliminates the need for continuous drug 
treatment. Thymectomy is indicated in all patients with generalized MG 
who are in the ages of puberty and upto 55 years. The recommendation of 
thymectomy in children, adults above 55 years of age and in patients with 
weakness restricted to ocular muscles in controversial. There is evidence 
that patients with Musk antibody postive MG may not respond to 
thymectomy. These is uncertainly as to whether the improvement was due 
to thymectomy or explicable by differences in baseline characteristics. This 
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will be clarified by an ongoing international prospective single blinded 
randomized trial of thymectomy in non-thymomatous myasthenia gravis. 
When there is a relapse following a response to initial surgery, repeat 
thymectomy can be considered. This is based on clinical suspicion 
(34)
. 
 
Immunosuppression: 
 Various drugs are used for immunosuppression either in various 
combinations or alone.  
 
These drugs are  
1) Glucocorticoids 
2) Azathioprine 
3) Cyclosporine 
4) Tacrolimus  
5) Mycophenolate mofetil  
6) High dose cyclophosphamide 
 
 Corticosteroids are the commonly used immunosuppressants in 
myasthenia gravis. Prednisolone causes marked improvement or complete 
relief of symptoms in more than 75% patients 
(20)
. There will be transitory 
exacerbation of weakness in a third to half of patients who are on high dose 
prednisolone which begin in 7 to 10 days of starting prednisolone and lasts 
for several days 
(20)
. Mycophenolate mofetil selectively blocks purine 
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synthesis leading to suppression of both T and B Cell proliferation. Studies 
indicate its efficacy in myasthenic gravis 
(21)
. Two randomized controlled 
trials did not show benefit of MMF over 20mg prednisolone daily 
(39)
 and 
failed to show significant steroid sparing effect of MMF in those on 
prednisolone 
(22)
. Tacrolimus may be effective in Myasthenia Gravis 
(40,17)
. 
Cyclophosphamide administered as monthly i.v. pulse doses has been useful 
in severe refractory generalized myasthenia gravis. 
(18,19)
. In a recent study, 
those who received immunosuppressants for minimum of 1 year, all forms 
benefited and the rate of remission or minimal manifestation was 85% in 
ocular myasthenia gravis 
(24)
. In thymoma associated myasthenia it is 47% 
(32)
. 
 
Plasmapheresis: 
 Plasma, which contains the pathogenic antibodies is mechanically 
separated from the blood cells which are returned to the patient. Usually five 
exchanges (3-4 L per exchange) is generally administered over a period of 
10-14 days. It gives a short term reduction in AchR antibodies with clinical 
improvement. Plasmapheresis is also indicated in patients with thymoma 
prior to surgery to improve the patients condition. 
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Intravenous Immunoglobulin: 
 The indication for the use of IVIg are to produce a rapid improvement 
and also prior to thymectomy. The advantages of this immunoglobulin are 
that it does not require special equipment or a large bore venous access. The 
usual dose in 2g/kg, administered over 5 days (400 mg/kg/day). 
Improvement occurs in 70% of patients, beginning during treatment or 
within a week and continuing for weeks to months. Adverse reactions to 
immunoglobulin are not serious and include headache, chills, fever, fluid 
overload, rarely aseptic meningitis, renal failure, stroke and leukopenia. 
Lyophilized forms of IVIg are reported to produce increased incidence of 
adverse events in neuromuscular disease. Refractory exacerbations of 
Myasthenia Gravis can be treated with IVIg as supported by Class I 
evidence 
(41)
. A placebo-controlled double blind recent trial showed rapid 
improvement in moderate to severe weakness after IVIg 
(23)
.  
 
Management of Myasthenic crisis: 
 Myasthenic crisis is defined as a exacerbation of weakness sufficient 
to endanger life. It is due to respiratory failure caused by diaphragmatic and 
intercostal muscle weakness. Patients are to be managed in an intensive care 
unit. Most common cause of crisis is intercurrent infection. It should be 
treated with effective antibiotic therapy, respiratory assistance and 
pulmonary physiotherapy. Plasmapheresis or IVIg is helpful in hastening 
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recovery. Non-invasive mechanical ventilation with bilevel positive-
pressure ventilation will avoid the need for intubation in patients in crisis 
without hypercapnia 
(28)
. Retrospective studies suggest that both IVIg and 
plasmapheresis are equally effective in disease stabilization 
(26)
. Other study 
suggest that plasmapheresis is superior in producing more rapid respiratory 
improvement 
(27)
. 
 
Newer Treatments: 
 Anti-musk antibodies positive myasthenia gravis will improve with 
rituximab 
(5,8)
. Etanercept is a recombinant human tumor necrosis factor 
receptor:FC. This shows improvement in myasthenia gravis 
(42)
. 
Compliment inhibition is effective in experimental myasthenia gravis and 
clinical trials are going on in humans 
(43)
. Autologous stem cell 
transplantation has been done in refractory myasthenia gravis but its role in 
myasthenia is unclear. 
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MATERIALS AND METHODS 
 
 In this open prospective study, patients admitted between 01.10.2012 
and 01.12.2013 in the Neurology ward, Medical ward and IMCU of Rajiv 
Gandhi Government General Hospital, Madras Medical College with 
symptoms and signs of myasthenic crisis, fulfilling the inclusion and 
exclusion criterias were enrolled after explaining the study and getting 
consent for the study. The study was previously approved by the 
Institutional Ethical Committee. 
 
Inclusion Criteria: 
 Patients who developed symptoms and signs of myasthenic crisis and 
who are admitted in Neurology ward, Medical ward and IMCU are 
registered for the study. 
 
Exclusion Criteria: 
1. Patients who are diagnosed to have other Medical and Surgical 
conditions. 
2. Other co-morbid conditions like HIV, Malignancy. 
3. Congenital myasthenic syndrome. 
4. Renal failure 
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5. Hepatic failure 
6. Patients with perioperative respiratory crisis associated with 
thymectomy. 
7. Pregnant Patients :  
These patients were excluded from the study. 
 
Methods and Analysis: 
 Patients with myasthenic crisis who are admitted in Neurology ward, 
Medical ward and IMCU were enrolled. Detailed history and physical 
examination findings were recorded.  
 
 All baseline investigations like Urine Routine, Complete Blood 
Counts, RFT, LFT were done.  
 
 X-Ray chest or CT-Chest, MRI Imaging of Brain, Brain stem and 
Spinal cord were done. ENMG and repetitive nerve stimulation were done 
in all patients. Anti-Acetyl cholinesterase and Anti-musk antibodies were 
measured in the blood whenever possible. Thyroid function tests were also 
carried out in some patients. 
 
The following parameters are analysed: 
1. Demographic Data 
31 
 
2. Duration of illness 
3. Predisposing factors 
4. Clinical features 
5. Associated complications 
6. Duration of mechanical ventilation 
7. Ventilator associated complications 
8. Treatment received 
9. Outcome of patients. 
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RESULTS & OBSERVATIONS 
AGE IN YEARS 
 
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
Below 
30 
4 16.0 16.0 16.0 
31-40 9 36.0 36.0 52.0 
41-50 5 20.0 20.0 72.0 
51-60 5 20.0 20.0 92.0 
Above 
60 
2 8.0 8.0 100.0 
Total 25 100.0 100.0  
 
 
Age in years
Age in years
Above 6051-6041-5031-40Below 30
F
re
q
u
e
n
c
y
10
8
6
4
2
0
 
33 
 
 
 
DESCRIPTIVE STATISTICS 
 
 N Minimum Maximum Mean 
Std. 
Deviation 
Age in years 25 17 65 42.08 13.086 
Valid N 
(listwise) 
25     
 
 
 
SEX 
 
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
Male 14 56.0 56.0 56.0 
Female 11 44.0 44.0 100.0 
Total 25 100.0 100.0  
 
 
Sex
Female
Male
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Correlations 
 
  
Disease 
Duration 
(Days) 
Duration of 
Crisis (Days) 
Disease Duration 
(Days) 
Pearson Correlation 1 .043 
Sig. (2-tailed) . .839 
N 25 25 
Duration of Crisis 
(Days) 
Pearson Correlation .043 1 
Sig. (2-tailed) .839 . 
N 25 25 
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PREDISPOSING FACTOR 
 
 
 
 
Predisposing Factor
Predisposing Factor
VIRAL FE
UTI
URI
SPINE TB
RESP. IN
PNEUNOMI
FEVER
ENTERIC
ASPIRATI
-
F
re
q
u
e
n
c
y
12
10
8
6
4
2
0
 
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
- 10 40.0 40.0 40.0 
Aspirati 2 8.0 8.0 48.0 
Enteric 1 4.0 4.0 52.0 
Fever 2 8.0 8.0 60.0 
Pneunomi 1 4.0 4.0 64.0 
Resp. In 4 16.0 16.0 80.0 
Spine TB 1 4.0 4.0 84.0 
URI 2 8.0 8.0 92.0 
UTI 1 4.0 4.0 96.0 
Viral fe 1 4.0 4.0 100.0 
Total 25 100.0 100.0  
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Positive Negative Total 
Count % Count % Count % 
Ptosis 19 76.00 6 24.00 25 100.00 
Diplopia 14 56.00 11 44.00 25 100.00 
Facial weakness 7 28.00 18 72.00 25 100.00 
Chewing 
difficulty 
21 84.00 4 16.00 25 100.00 
Dys phagia 19 76.00 6 24.00 25 100.00 
Nasal 
Regurgitation 
12 48.00 13 52.00 25 100.00 
Aspiration 3 12.00 22 88.00 25 100.00 
Breath difficulty 24 96.00 1 4.00 25 100.00 
Speech - Nasal 10 40.00 15 60.00 25 100.00 
Speech - Dys 
arthric 
22 88.00 3 12.00 25 100.00 
Limb 
/Generalised  
weakness - 
Symmetric - 
Prox 
20 80.00 5 20.00 25 100.00 
Limb 
/Generalised  
weakness - 
Symmetric - 
Dist 
19 76.00 6 24.00 25 100.00 
Limb 
/Generalised  
weakness - 
Asymmetric - 
Prox 
6 24.00 19 76.00 25 100.00 
Limb 
/Generalised  
weakness - 
Asymmetric - 
Dist 
5 20.00 20 80.00 25 100.00 
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MOTOR POWER - UL - RIGHT 
 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
4- 3 12.0 12.0 12.0 
4 17 68.0 68.0 80.0 
4+ 2 8.0 8.0 88.0 
5 3 12.0 12.0 100.0 
Total 25 100.0 100.0  
 
 
MOTOR POWER - UL - LEFT 
 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
3 1 4.0 4.0 4.0 
4- 3 12.0 12.0 16.0 
4 16 64.0 64.0 80.0 
4+ 2 8.0 8.0 88.0 
5 3 12.0 12.0 100.0 
Total 25 100.0 100.0  
 
 
MOTOR POWER - LL - RIGHT 
 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
4- 2 8.0 8.0 8.0 
4 20 80.0 80.0 88.0 
4+ 1 4.0 4.0 92.0 
5 2 8.0 8.0 100.0 
Total 25 100.0 100.0  
 
 
MOTOR POWER - LL - LEFT 
 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
4- 2 8.0 8.0 8.0 
4 20 80.0 80.0 88.0 
4+ 1 4.0 4.0 92.0 
5 2 8.0 8.0 100.0 
Total 25 100.0 100.0  
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Complication
Respiratory Failur
Respiratory distre
Pneumonia / respir
Mild breathlessnes
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DESCRIPTIVE STATISTICS 
 
 N Minimum Maximum Mean 
Std. 
Deviation 
Disease Duration 
(Days) 
25 7 1460 627.16 521.380 
Interval from Sym 
To Crisis (Days) 
25 7 1460 439.36 413.842 
Duration of Crisis 
(Days) 
25 2 30 9.64 8.336 
Duration IMCU 
Stay (Days) 
25 3 40 13.32 9.915 
Valid N (listwise) 25     
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TIME FOR DISEASE STABILIZATION  
OUTCOME CROSS TABULATION 
 
    
Outcome 
Total Expired Survive 
Time for 
Disease 
Stabilization 
<= 7 Count 2 8 10 
% within 
Time for 
Disease 
Stabilization 
20.0% 80.0% 100.0% 
% within 
Outcome 
50.0% 61.5% 58.8% 
8-14 Count 1 2 3 
% within 
Time for 
Disease 
Stabilization 
33.3% 66.7% 100.0% 
% within 
Outcome 
25.0% 15.4% 17.6% 
15-21 Count 0 1 1 
% within 
Time for 
Disease 
Stabilization 
.0% 100.0% 100.0% 
% within 
Outcome 
.0% 7.7% 5.9% 
22-30 Count 1 2 3 
% within 
Time for 
Disease 
Stabilization 
33.3% 66.7% 100.0% 
% within 
Outcome 
25.0% 15.4% 17.6% 
Total Count 4 13 17 
% within 
Time for 
Disease 
Stabilization 
23.5% 76.5% 100.0% 
% within 
Outcome 
100.0% 100.0% 100.0% 
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IVIG  STEROID 
 
 
    
Steroid 
Total Positive Negative 
IVIG Positive Count 3 0 3 
% within 
IVIG 
100.0% .0% 100.0% 
% within 
Steroid 
15.0% .0% 12.0% 
Negative Count 17 5 22 
% within 
IVIG 
77.3% 22.7% 100.0% 
% within 
Steroid 
85.0% 100.0% 88.0% 
Total Count 20 5 25 
% within 
IVIG 
80.0% 20.0% 100.0% 
% within 
Steroid 
100.0% 100.0% 100.0% 
 
 
Chi-Square Tests 
 
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-
Square 
.852(b) 1 .356   
Continuity 
Correction(a) 
.024 1 .878   
Likelihood Ratio 1.438 1 .230   
Fisher's Exact 
Test 
   1.000 .496 
Linear-by-Linear 
Association 
.818 1 .366   
N of Valid Cases 25     
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PLASMA PHERESIS STEROID 
 
    
Steroid 
Total Positive 
Negativ
e 
Plasma 
Pheresis 
Positive Count 15 4 19 
% within 
Plasma 
Pheresis 
78.9% 21.1% 100.0% 
% within 
Steroid 
75.0% 80.0% 76.0% 
Negative Count 5 1 6 
% within 
Plasma 
Pheresis 
83.3% 16.7% 100.0% 
% within 
Steroid 
25.0% 20.0% 24.0% 
Total Count 20 5 25 
% within 
Plasma 
Pheresis 
80.0% 20.0% 100.0% 
% within 
Steroid 
100.0% 100.0% 100.0% 
 
 
Chi-Square Tests 
 
  Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-
Square 
.055(b) 1 .815     
Continuity 
Correction(a) 
.000 1 1.000     
Likelihood Ratio .057 1 .812     
Fisher's Exact 
Test 
      1.000 .657 
Linear-by-Linear 
Association 
.053 1 .819     
N of Valid Cases 25         
a  Computed only for a 2x2 table 
b  3 cells (75.0%) have expected count less than 5. The minimum expected count 
is 1.20. 
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IVIG 
 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Positive 3 12.0 12.0 12.0 
  Negative 22 88.0 88.0 100.0 
  Total 25 100.0 100.0   
 
 
PLASMA PHERESIS 
 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Positive 19 76.0 76.0 76.0 
  Negative 6 24.0 24.0 100.0 
  Total 25 100.0 100.0   
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STEROID 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Positive 20 80.0 80.0 80.0 
  Negative 5 20.0 20.0 100.0 
  Total 25 100.0 100.0   
 
 
IVIG, PLASMA AND STERIOD 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Positive 24 96.0 96.0 96.0 
  Negative 1 4.0 4.0 100.0 
  Total 25 100.0 100.0   
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IVIG OUTCOME 
 
 
    
Outcome 
Total Expired Survive 
IVIG Positive Count 1 2 3 
% within 
IVIG 
33.3% 66.7% 100.0% 
% within 
Outcome 
25.0% 9.5% 12.0% 
Negative Count 3 19 22 
% within 
IVIG 
13.6% 86.4% 100.0% 
% within 
Outcome 
75.0% 90.5% 88.0% 
Total Count 4 21 25 
% within 
IVIG 
16.0% 84.0% 100.0% 
% within 
Outcome 
100.0% 100.0% 100.0% 
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Chi-Square Tests 
 
  Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-
Square 
.762(b) 1 .383     
Continuity 
Correction(a) 
.001 1 .973     
Likelihood Ratio .639 1 .424     
Fisher's Exact Test       .422 .422 
Linear-by-Linear 
Association 
.732 1 .392     
N of Valid Cases 25         
a  Computed only for a 2x2 table 
b  3 cells (75.0%) have expected count less than 5. The minimum expected count 
is .48. 
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PLASMA PHERESIS OUTCOME 
 
  
Outcome 
Total 
Expired Survive 
Plasma 
Pheresis 
Positive Count 3 16 19 
% within 
Plasma 
Pheresis 
15.8% 84.2% 100.0% 
% within 
Outcome 
75.0% 76.2% 76.0% 
Negative Count 1 5 6 
% within 
Plasma 
Pheresis 
16.7% 83.3% 100.0% 
% within 
Outcome 
25.0% 23.8% 24.0% 
Total Count 4 21 25 
% within 
Plasma 
Pheresis 
16.0% 84.0% 100.0% 
% within 
Outcome 
100.0% 100.0% 100.0% 
 
 
Chi-Square Tests 
 
  Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-
Square 
.003(b) 1 .959     
Continuity 
Correction(a) 
.000 1 1.000     
Likelihood Ratio .003 1 .959     
Fisher's Exact 
Test 
      1.000 .694 
Linear-by-Linear 
Association 
.003 1 .960     
N of Valid Cases 25         
a  Computed only for a 2x2 table 
b  2 cells (50.0%) have expected count less than 5. The minimum expected count 
is .96. 
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AGE IN YEARS OUTCOME CROSSTABULATION 
 
    
Outcome 
Total Expired Survive 
Age in years Below 30 Count 0 4 4 
% within Age 
in years 
.0% 100.0% 100.0% 
% within 
Outcome 
.0% 19.0% 16.0% 
31-40 Count 1 8 9 
% within Age 
in years 
11.1% 88.9% 100.0% 
% within 
Outcome 
25.0% 38.1% 36.0% 
41-50 Count 2 3 5 
% within Age 
in years 
40.0% 60.0% 100.0% 
% within 
Outcome 
50.0% 14.3% 20.0% 
51-60 Count 1 4 5 
% within Age 
in years 
20.0% 80.0% 100.0% 
% within 
Outcome 
25.0% 19.0% 20.0% 
Above 60 Count 0 2 2 
% within Age 
in years 
.0% 100.0% 100.0% 
% within 
Outcome 
.0% 9.5% 8.0% 
Total Count 4 21 25 
% within Age 
in years 
16.0% 84.0% 100.0% 
% within 
Outcome 
100.0% 100.0% 100.0% 
 
 
Chi-Square Tests 
 
  Value df Asymp. Sig. (2-
sided) 
Pearson Chi-Square 3.505(a) 4 .477 
Likelihood Ratio 3.970 4 .410 
Linear-by-Linear Association .330 1 .566 
N of Valid Cases 25     
a  9 cells (90.0%) have expected count less than 5. The minimum expected count is .32. 
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T-Test 
 
Group Statistics 
 
  Outcome N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
Age in years Expired 4 47.50 9.539 4.770 
Survive 21 41.05 13.596 2.967 
Disease 
Duration 
(Days) 
Expired 4 1460.00 .000 .000 
Survive 
21 468.52 401.318 87.575 
Duration 
IMCU Stay 
(Days) 
Expired 4 12.00 12.193 6.096 
Survive 
21 13.57 9.760 2.130 
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INDEPENDENT SAMPLES TEST 
 
  
Levene's Test for 
Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Differen
ce 
Std. 
Error 
Differen
ce 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Age in years Equal variances 
assumed 1.156 .293 .900 23 .377 6.45 7.167 -8.374 21.279 
Equal variances 
not assumed     1.149 5.644 .297 6.45 5.617 -7.505 20.410 
Disease Duration 
(Days) 
Equal variances 
assumed 12.772 .002 4.856 23 .000 991.48 204.160 569.140 
1413.81
2 
Equal variances 
not assumed     11.321 20.000 .000 991.48 87.575 808.799 
1174.15
4 
Duration IMCU 
Stay (Days) 
Equal variances 
assumed .385 .541 -.285 23 .778 -1.57 5.516 -12.982 9.839 
Equal variances 
not assumed     -.243 3.769 .820 -1.57 6.458 -19.944 16.801 
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HT  OUTCOME 
 
 
    
Outcome 
Total Expired Survive 
HT Present Count 1 0 1 
% within 
HT 
100.0% .0% 100.0% 
% within 
Outcome 
25.0% .0% 4.0% 
Absent Count 3 21 24 
% within 
HT 
12.5% 87.5% 100.0% 
% within 
Outcome 
75.0% 100.0% 96.0% 
Total Count 4 21 25 
% within 
HT 
16.0% 84.0% 100.0% 
% within 
Outcome 
100.0% 100.0% 100.0% 
 
 
 Chi-Square Tests 
 
  Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-
Square 
5.469(b) 1 .019     
Continuity 
Correction(a) 
.896 1 .344     
Likelihood Ratio 3.899 1 .048     
Fisher's Exact 
Test 
      .160 .160 
Linear-by-Linear 
Association 
5.250 1 .022     
N of Valid Cases 25         
 
a  Computed only for a 2x2 table 
b  3 cells (75.0%) have expected count less than 5. The minimum expected count is 
.16. 
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DM  OUTCOME 
 
 
    
Outcome 
Total Expired Survive 
DM Present Count 1 4 5 
% within 
DM 
20.0% 80.0% 100.0% 
% within 
Outcome 
25.0% 19.0% 20.0% 
Absent Count 3 17 20 
% within 
DM 
15.0% 85.0% 100.0% 
% within 
Outcome 
75.0% 81.0% 80.0% 
Total Count 4 21 25 
% within 
DM 
16.0% 84.0% 100.0% 
% within 
Outcome 
100.0% 100.0% 100.0% 
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Chi-Square Tests 
 
  Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-
Square 
.074(b) 1 .785     
Continuity 
Correction(a) 
.000 1 1.000     
Likelihood Ratio .071 1 .790     
Fisher's Exact Test       1.000 .617 
Linear-by-Linear 
Association 
.071 1 .789     
N of Valid Cases 25         
a  Computed only for a 2x2 table 
b  3 cells (75.0%) have expected count less than 5. The minimum expected count is 
.80. 
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DISCUSSION 
 
Myasthenia crisis is very often encountered in IMCU as neurological 
emergency. Treatment of myasthenic crisis is very cost effective as it requires 
ventilator support, IVIg, Plasmapheresis, technical expertise and skilled 
nursing care. 
 
In our study the minimum age of onset of crisis is 17 years and 
maximum age of onset is 65 years. The maximum number of cases (36%) (9 
patients), occurred in the age group of 31-40 with male predominance (5 males 
and 4 females). The mean age at presentation of crisis was 42.08 + 13.086 
(44)
. 
 
Sex distribution of crisis was 56% for males (14 cases) and 44% for 
females (11 cases). The sex distribution and mean age of onset of crisis are 
similar to the study conducted at All India Institute of Medical Sciences, New 
Delhi 
(44)
. 
 
Predisposing Factors: 
 The most common predisposing factor in our patients are respiratory 
infection (28%) which includes upper, lower respiratory tract infection and 
pneumonia. These results are comparable to that of the other studies 
(44,45,46)
. 
The other predisposing factors are aspiration, tuberculosis, UTI, Enteric fever, 
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and viral fever. Hence adequate prevention and treatment of various infections 
in myasthenic patients help to reduce the incidence of crisis. Predisposing 
factor is the most important and independent risk factor against the duration 
and severity of preexisting myasthenia gravis. 
 
Clinical Profile: 
 Breathing difficulty was the predominant symptom in all the patients 
(96%) followed by speech difficulty (88%) and chewing difficulty (84%). 
Limb and generalized weakness is also another predominant symptom (80%) 
in all the patients. Other symptoms like ptosis (76%), Dysphagia (76%), 
diplopia (56%), nasal regurgitation (48%) and facial weakness (28%) are in the 
decreasing frequency. Our patients presented with predominant bulbar 
symptoms similar to other studies 
(44,45,26)
. 
 
Disease Duration and Crisis:  
 Our patients had a minimum disease duration of 7 days and maximum 
of 1460 days and a mean of 627.16 days. The interval from symptom to the 
onset of crisis was 7 days (minimum) and maximum of 1460 days with a mean 
of 439.36 days. The duration of crisis ranged from 2 to 30 days with a mean of 
9.64 days. The duration of myasthenia gravis does not influence the 
occurrence of myasthenic crisis. Our study correlates with other studies. Three 
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patients presented itself with symptoms of crisis and later diagnosed to have 
myasthenic crisis.  
 
Time for disease stabilization and IMCU stay: 
 Patients were on mechanical ventilation for a minimum of 2 days and a 
maximum of 30 days. 2 patients died within one week of mechanical 
ventilation and another patient died one week after admission but within 2 
weeks. One patient died on the 30
th
 day of mechanical ventilation. Other 
patients improved of the symptoms. 8 patients were not intubated but were 
administered nasal O2 and became stable. The duration of IMCU stay also 
ranged from 3 days to 40 days with a mean of 13.32 days. 
 
Complications: 
 Three patients developed ventilator associated pneumonia (12%). One 
patient developed respiratory failure, autonomic dysfunction and shock within 
5 days of crisis. Another patient developed respiratory failure, pneumonia with 
pleural effusion and collapse of underlying lobe and pneumothorax on the 
opposite side with subcutaneous emphysema within 10 days of crisis. All those 
patients who developed VAP were on prolonged ventilation (30 days). This 
indicates that when patients are on ventilation for prolonged periods, they are 
more prone for associated complications. Comprehensive standard pulmonary 
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and ventilator care and hospital antibiotic usage guidelines can prevent these 
complications. 
 
Thymoma and Crisis: 
 6 patients had thymoma. Among them 3 were operated and 3 patients 
were advised to undergo operation. One patient who had thymoma and on 
prolonged ventilation for 30 days with VAP died on the 30
th
 day. Thymectomy 
was done in 5 patients with normal thymus and in 13 patients thymus was not 
removed. Though thymectomy was carried out on these patients, the beneficial 
effect of thymectomy will take longer than 1 to 2 years. 
 
Outcome: 
 Higher age is a risk factor and lesser age is a favourable factor for good 
outcome. Duration of myasthenia gravis does not have any role on the 
outcome of the patient. IMCU stay is a variable factor for the outcome of 
myasthenic patients.  
 
 Though patients on prolonged ventilation may be prone for VAP and 
other ventilator related complications, the better survival rate in ventilated 
patients outweigh the preventable ventilator related complications. Commonly 
in olden days, co-morbid conditions have a major negative impact on the 
outcome of the myasthenia crisis.  
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 Standardised myasthenia crisis treatment protocol and advanced ICU 
care setup minimizes the negative impact of the co-morbid conditions on 
myasthenic crisis. The therapeutic regimen should be tailored to the patients 
age, severity of crisis, circulatory status and comorbid conditions. Fixed 
standardized and combined treatment regimen is not suitable for each and 
every patient. As the sample size is very small, it needs further study.  
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CONCLUSION 
1. In our study, the commonest age group of presentation of myasthenic 
crisis is the fourth decade (36%). 
2. Male predominance (56%) was noted in our study. 
3. The most common predisposing factor is the respiratory infection (28%). 
4. In three patients, the presenting symptoms of myasthenia gravis was crisis 
itself. 
5. The mean duration of onset of myasthenia gravis to the onset of crisis was 
439.36 days. 
6. The duration of myasthenia gravis does not influence the occurrence of 
myasthenic crisis. 
7. Our patients presented with predominant bulbar symptoms with 
respiratory distress. 
8. Ventilator associated pneumonia and other respiratory complications 
influenced the outcome of treatment of myasthenic crisis. 
9. 32% of thymectomised patients had myasthenic crisis. 
10. Higher age is a risk factor and younger age is a favourable factor for good 
outcome. 
11. Duration of myasthenia gravis have no role on the outcome of crisis. 
12. The better survival rate in ventilated patients outweigh the preventable 
ventilator related complications. 
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PROFORMA 
 
Name :      Age :    Sex : 
 
Address :       Unit :   Ward : 
 
Present History: 
 
Symptoms:      Duration: 
 
Ptosis   : 
 
Diplopia   : 
 
Facial Weakness  : 
 
Chewing Difficulty : 
 
Dysphagia  : 
 
Nasal Regurgitation : 
 
Aspiration  : 
 
Breathing Difficulty : 
 
Speech Difficulty : 
 
Limb or Generalized Weakness: 
 
 
Past History: 
 
Diabetes Mellitus : 
 
Hypertension  : 
 
Tuberculosis  : 
 
Hepatitis  : 
 
Renal Disease  : 
 
Glaucoma  : 
 
Respiratory Infection : 
 
Thyroid Disorder : 
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Autoimmune Disorder: 
 
Personal History 
 
Smoking  : 
 
Alcohol Consumption : 
 
 
Physical Examination: 
 
Fever   : 
 
Anaemia  : 
 
Jaundice  : 
 
Tuberculosis Stigmata : 
   
Pedal Oedema  : 
  
Neck Swelling : 
 
 
Vitals: 
 
Pulse  :   BP :  Body Temperature : 
 
 
Neurological Examination: 
 
Consciousness 
 
Cranial Nerve Examination: 
 
Power :  Neck 
 
   Right Upper Limb   Left Upper Limb 
 
   Right Lower Limb   Left Lower Limb 
 
   Trunk Muscle Power 
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Other System Examination 
 
Laboratory Parameter 
 
Complete Blood Count  : 
 
Blood Sugar   : 
 
Blood Urea   : 
 
Serum Creatinine  : 
 
Serum Electrolytes  : 
 
Liver Function Tests  : 
 
Anti Ach-R Antibody  : 
 
Anti Musk Antibody  : 
 
Repetitive Nerve Stimulation : 
 
CT or MRI Brain  : 
 
X-ray Chest (or) CT-Chest : 
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